Close FDA cybersecurity deficiencies for surgical robotic systems - multi-element SBOMs, control-loop threat models, and OR-network security architecture views.
Last reviewed March 2026 · Reviewed against the FDA Feb 3, 2026 final premarket cybersecurity guidance.
Deficiency letters for surgical robotic systems are usually heavy on three items: the multi-element SBOM that wasn't, the threat model that didn't include the OR-network and instrument-tower trust boundaries, and the security architecture view that conflated the patient cart with the surgeon console. Our 48-hour gap analysis identifies the architectural disclosures the reviewer is actually asking for - usually four discrete views: global system, multi-patient harm, updateability, and security use cases - and which are missing or insufficient in your current package.
The second cluster of deficiencies in this segment is essential-performance-adjacent: cyber findings on motion control or energy delivery treated as IT findings rather than as risk controls under IEC 60601-1's essential performance framework. Reviewers will reject responses that don't connect the cyber finding to the essential performance impact and the risk-control treatment. We rebuild that connection in your hazard analysis and risk file. The third cluster is around the postmarket plan: surgical robots are deployed in OR fleets and need a credible field-update story with a CVD program. We deliver the resubmission package as eSTAR-ready, structured for the reviewer who issued the letter, with traceability between deficiency item and response artifact.
Four phases, fixed fee, scoped to surgical robotics architecture from kickoff onward.
Architecture review, attack-surface walkthrough, and threat-model alignment with your team. Written scope in 24 hours.
Every STRIDE entry in your threat model is matched to a planned test case so reviewers see one-to-one coverage.
Device, cloud, mobile, BLE/RF, and OTA channels exercised in parallel by senior engineers - not a single web-app scan.
eSTAR-format report with findings, CVSS, remediation, and retests until every finding with uncontrolled risk is closed.
The patterns we hit in this segment, this service, again and again.
Reviewer expects per-compute-element SBOM. Submission had one CycloneDX for the main node only.
Pen test results attached but not analyzed against essential performance. Resolved with risk-file linkage.
'Updateability view' submitted but doesn't cover joint-controller or FPGA update channels. Rebuilt to actual architecture.
Threat model stops at the integration tower. Reviewer asks about imaging / energy-generator pass-through; gap addressed.
"Blue Goat Cyber takes the burden off our engineers and makes FDA cybersecurity requirements easy to understand. Their expertise and smooth process mean we can focus on our product, not the paperwork. The organized documentation, perfectly formatted for eSTAR, saves us countless hours."
The same deliverables the parent FDA Deficiency Response service ships with - tuned to your surgical robotics architecture.
Reviewer-format documents ready to drop straight into the cybersecurity attachments of your submission - no reformatting on your side.
The Surgical Robotics baseline, plus the call-outs that matter for fda deficiency response in this segment.
Cyber findings on motion or energy delivery must be analyzed under essential performance - reviewers reject responses that don't.
Surgical-robotics fleets need a real postmarket cyber plan. Reviewers in this segment ask about it explicitly.
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
The questions buyers in this segment actually ask before scoping a fda deficiency response engagement.
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
The most common cybersecurity deficiencies in 510(k), De Novo, and PMA submissions, what triggers each one and how to fix it before you file. Aligned to the FDA February 2026 final guidance and Section 524B.
PreSTAR vs eSTAR explained: PreSTAR is the voluntary FDA template for Q-Submissions, eSTAR is required for 510(k) and De Novo. How cybersecurity carries across.
Medical device cybersecurity at each study stage: rodent, large animal, primate, and human trials, and what the FDA expects before your IDE and marketing submission.
What a medical device security advisor does after FDA clearance: keeping the threat model and SBOM current, rating vulnerabilities, and answering hospitals.
Teams in this segment commonly bundle these alongside fda deficiency response.
A 30-minute call with a senior engineer who has done this in surgical robotics before - not a sales rep.
